Intellia Therapeutics Inc
NTLA
$132.68
+433.3% (1 year change)
$132.68
+433.3% (1 year change)
$9.68 Billion
The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.$22.17 - $202.73
The lowest and highst price in the last 52 weeks.-52.33x
The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.$0.00 (0.0%)
Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).| Market Cap | $9.68 Billion |
| Enterprise Value | $9.15 Billion |
| Dividend Yield | $0.00 (0.0%) |
| 1 Year Return | +433.3% |
| 52-Week High | $202.73 |
| 52-Week Low | $22.17 |
| Beta | 2.21 |
| Outstanding Shares | 73.5 Million |
| Avg 30 Day Volume | 894 Thousand |
| P/E Ratio | -52.33 |
| PEG | -46.55 |
| Earnings per Share | -$2.90 |
| Price to Sales Ratio | Infinity |
| Price to Book Ratio | 22.11 |
| Revenue to Enterprise Value | 218.95 |
| EBIT to Enterprise Value | -49.23 |
| Total Debt to Enterprise Value | 0.0 |
| Debt to Equity | 0.0 |
| Revenue | $41.8 Million |
| Gross Profit | $41.8 Million |
| EBIT | -$186 Million |
| Net Income | -$185 Million |
| Profit Margin | -442.58% |
| Quarterly Earnings Growth (YoY) | +112.4% |
| Return on Equity | -37.4% |
| Return on Assets | -27.53% |
| Return on Invested Capital | -31.08% |
No purchases
527,926 shares sold (6 transactions)
No purchases
176,961 shares sold (10 transactions)
No purchases
25,134 shares sold (4 transactions)
No purchases
No sells
CEO: John Leonard
Employees: 211
Industry: Pharmaceutical Preparation Manufacturing
Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. Intellia Therapeutics was founded in May 2014 to develop biopharmaceuticals using CRISPR.
Related Stocks: VOO , VYM , DFAC , DFAX , AVUV , VFVA , AVEM , AVDV , SCHA , SCHF , NTLA , BKI , QQQ ,
Related Stocks: HD , NTLA , GDX , SLQT , NVDA , IHI , KLDW , FIGS , WKME , QUS , PFIX , JEPI , WORK , WYNN , ZEN , EPC , ACM , VLDR ,
Intellia Therapeutics Inc (NTLA) shares closed today 10.4% lower than it did at the end of yesterday. The stock is currently up 121.9% year-to-date, up 426.2% over the past 12 months, and up 699.4%...
